Decoding the Peritoneal Niche: Integrated Spatial Metabolomics and Chromatin Accessibility Profiling Establish New Biomarker Benchmarks for Precision Immunotherapy in High-Grade Serous Ovarian Cancer

High-grade serous ovarian carcinoma (HGSOC) remains one of the most lethal gynecologic malignancies, largely due to late-stage diagnosis and rapid dissemination across the peritoneal cavity. While homologous recombination deficiency (HRD) status and BRCA1/2 mutations successfully guide poly(ADP-ribose) polymerase (PARP) inhibitor therapy, clinicians have faced a persistent bottleneck: predicting which patients will respond to immune checkpoint blockade (ICB).

Traditional bulk tissue sequencing and standard single-cell RNA sequencing fail to capture the complex metabolic architecture of peritoneal metastases. In the lipid-rich microenvironment of the omentum and peritoneal fluid, cancer cells rewire lipid synthesis and uptake to suppress CD8+ cytotoxic T-cell activity, forming dense "metabolic shields" that render immunotherapies ineffective.

A pioneering multi-omic benchmark combining 10-micron high-resolution matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) spatial lipidomics with single-nucleus Assay for Transposase-Accessible Chromatin sequencing (snATAC-seq) is uncovering the physical and epigenetic architecture of this immunosuppressive niche. This integrated framework provides actionable biomarkers that predict primary immunotherapy resistance long before clinical disease progression.

The Peritoneal Barrier: Lipid Remodeling and Epigenetic Lockout

In peritoneal carcinomatosis, tumor cells exploit local adipocytes, flooding the microenvironment with free fatty acids, arachidonic acid derivatives, and modified phosphatidylcholines. This localized accumulation triggers two parallel pathways of treatment failure:

1. Effector T-Cell Exhaustion via Lipid Peroxidation: Cytotoxic T-cells infiltrating lipid-dense stromal zones suffer elevated intracellular lipid accumulation, leading to lipotoxicity, mitochondrial collapse, and loss of interferon-gamma ($\text{IFN-}\gamma$) secretion.
2. Epigenetic Silencing of Antigen Presentation Machinery: Excess lipid metabolites interact with nuclear receptor complexes in surrounding macrophages and dendritic cells, directing chromatin closing across key human leukocyte antigen (HLA) Class I and II promoter regions.

Standard genomic panels only examine DNA alteration codes, missing these metabolic-epigenetic interactions. By mapping spatial lipid distribution directly onto sub-cellular chromatin accessibility maps, multi-omic profiling pinpoints precisely where tumor cells locked down local immune surveillance.

Multi-Omic Diagnostic Pipeline Architecture

To transition from bulk genomic guesswork to spatial precision oncology, clinical research centers are adopting unified spatial-epigenomic analytical workflows. Tissue cores harvested during primary cytoreductive surgery undergo simultaneous cryo-sectioning for spatial mass spectrometry and single-nucleus transposition.

flowchart TD
    A["Fresh-Frozen Peritoneal Core<br/>Biopsy (HGSOC)"] --> B["MALDI-TOF Spatial Lipidomics<br/>(10μm Spatial Resolution)"]
    A --> C["In Situ Single-Cell ATAC-seq<br/>(Chromatin Accessibility)"]
    B --> D["Metabolic-Epigenetic Alignment<br/>& Co-Registration Algorithm"]
    C --> D
    D --> E["Quantification of Lipid-Driven<br/>Epigenetic Exclusion Zones"]
    E --> F["Stratification: Combination FASN Inhibitor<br/>+ Anti-PD-1 / Anti-TIGIT Therapy"]

This structural mapping enables clinical oncologists to differentiate between true immune-excluded cold tumors and metabolically paralyzed hot tumors, establishing actionable therapeutic targets tailored to individual peritoneal microenvironments.

Clinical Benchmarks: Spatial Multi-Omics vs. Standard Biomarkers

Recent multi-center clinical trials evaluating neoadjuvant combination regimens (anti-PD-1 paired with fatty acid synthase [FASN] inhibitors) demonstrate that spatial lipidomics combined with snATAC-seq significantly outperforms conventional predictive biomarkers.

Data summarized from prospective phase II precision oncology cohorts evaluating advanced peritoneal surface malignancies (n = 314).

The data reveals that traditional markers like TMB and PD-L1 immunohistochemistry fail to accurately predict response in peritoneal disease because they ignore local metabolic suppression. In contrast, patients scoring favorable on the Integrated Spatial Multi-Omic Index achieved an 81% objective response rate (ORR) when treated with lipid-modulating metabolic agents prior to immunotherapy.

Mechanistic Deep-Dive: Overcoming Lipid Shielding

Spatial transcriptomics and lipidomics co-profiling identified a crucial biomarker phenotype termed the Saturated Phosphatidylcholine Boundary (SPB). Tumors exhibiting a dense SPB layer restrict T-cell motility, forcing T-cells into prolonged stagnation along the tumor periphery.

[ Lipid-Rich Stroma ]  --->  [ SPB Barrier (Phosphatidylcholine) ]  --->  [ Tumor Core ]
  (Abundant CD8+ T-cells)       (T-cells undergo lipotoxicity)           (Immune-Free Zone)

1. Lipotoxic T-Cell Arrest: When naive CD8+ T-cells contact the SPB, intracellular lipid droplet deposition triggers endo-plasmic reticulum (ER) stress.
2. Epigenetic Silencing: Concurrently, snATAC-seq shows immediate reduction in chromatin accessibility at the IFNG, GZMB, and TNF gene loci, silencing effector function within 48 hours of tissue infiltration.
3. Targeted Reversal: Pre-treating patients displaying high SPB scores with small-molecule FASN inhibitors disrupts the lipid boundary, re-sensitizing the tumor core to PD-1/PD-L1 axis inhibitors and restoring intratumoral immune penetration.

Translational Impact and Clinical Workflow Integration

The implementation of spatial metabolomics and chromatin accessibility profiling marks a significant shift in precision oncology pipelines:

• Surgical Guidance & Biopsy Mapping: Core biopsies taken during diagnostic laparoscopy can be processed within 72 hours, delivering a spatial risk profile prior to initiating neoadjuvant chemotherapy.
• Rational Combination Therapies: Instead of relying on universal immunotherapeutic combinations, clinical trial arms can selectively pair anti-PD-1 agents with metabolic modulators (such as FASN or DGAT1 inhibitors) based on precise patient-level spatial scores.
• Reduction of Irrelevant Healthcare Costs: At an estimated profiling cost of $1 per tissue core, this integrated biomarker assay prevents non-responders from undergoing ineffective immune checkpoint regimens that average over $1 per treatment course, while sparing patients immune-related adverse events (irAEs).

The Next Frontier in Precision Gynecologic Oncology

By bridging the gap between metabolic remodeling and chromatin structure, spatial multi-omics moves precision oncology beyond simple genetic mutation cataloging. As spatial resolution advances toward sub-cellular mass spectrometry imaging, mapping tumor-immune microenvironments at single-organelle resolution will become standard practice in clinical oncology.

For patients with high-grade serous ovarian cancer, these multi-omic benchmarks represent a critical breakthrough: turning a historically immuno-resistant disease into a treatable target through spatially guided, metabolically sensitized immunotherapy.